Predictive factors and the management of hyperglycemia in patients with acromegaly and Cushing's disease receiving pasireotide treatment: post hoc analyses from the SOM230B2219 study

What Was Tested

The paper reports a study of Somatostatin and Pasireotide, published as a randomized controlled trial.

The prospective, randomized, Phase IV SOM230B2219 (NCT02060383) trial was designed to assess optimal management of pasireotide-associated hyperglycemia.

Why It Was Studied

Pasireotide, a somatostatin receptor ligand, is approved for treating acromegaly and Cushing's disease (CD).

Hyperglycemia during treatment can occur because of the drug's mechanism of action, although treatment discontinuation is rarely required.

How the Study Was Run

The design is described as randomized.

The participants were allocated by chance, so the Somatostatin group and the comparison group should start out alike.

Those who did not need antihyperglycemic medication, were managed with metformin, or received insulin from baseline entered an observational arm ending at 16 weeks.

Those who required additional/alternative antihyperglycemic medication to metformin were randomized to incretin-based therapy or insulin for an additional 16 weeks.

Logistic-regression analyses evaluated quantitative and qualitative factors for requiring antihyperglycemic medication during pre-randomization.

What Was Measured

The subject headings attached to it are Acromegaly, Blood Glucose, Diabetes Mellitus, Hyperglycemia, Hypoglycemic Agents, Insulin and Metformin.

The authors tagged it with the keywords Cushing’s disease, glucose intolerance, pasireotide and pituitary adenoma.

What This Means in Plain Language

The paper is a randomized study of Somatostatin and Pasireotide.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2024 (Frontiers in endocrinology), a journal based in Switzerland.

More context: the Somatostatin compound page and the Pasireotide compound page, all human trials.